Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer

Exclusion Criteria

• •Patients with an active infection \> 38.5 degrees Celsius within 3 days of the first scheduled day of protocol treatment
• •Patients with active central nervous system (CNS) metastasis. Patients with stable CNS disease, who have undergone radiotherapy at least 4 weeks prior to the planned first protocol treatment and who have been on a stable dose of corticosteroids for 2 weeks are eligible for the trial.
• •History of prior malignancy within the past 5 years except for curatively treated basal cell carcinoma of the skin; cervical intra-epithelial neoplasm, or localized prostate cancer with a current prostate specific antigen (PSA) of \< 1.0 mg/dL
• •Patients with known hypersensitivity to any of the components of oxaliplatin or docetaxel
• •Patients who have had prior chemotherapy for lung cancer
• •Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment
• •Grade 2 peripheral neuropathy
• •Patients who are pregnant or lactating
• •Any other medical condition, including mental illness or substance abuse deemed by the investigator to be likely to interfere with the patients' ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
• •History of allogeneic transplant
• •Known HIV, hepatitis B or C (active, previously treated, or both)